The product is released as colchicine Ph. Eur., a non-proprietary pharmacopoeial active pharmaceutical ingredient identified by CAS 64-86-8, molecular formula C22H25NO6, and relative molecular mass 399.44. The material is not a formulated dosage form; it is supplied as a crystalline powder for further manufacture into tablets, capsules, granules, oral solutions, and injectable presentations. Pharmaceutical-grade colchicine is distinguished from technical-grade or botanical-extract material by current European Pharmacopoeia monograph conformance, ICH Q3C residual solvent control, ICH Q3D elemental impurity risk assessment, and documented batch-to-batch particle size control. Each lot is released with a certificate of analysis that includes identification by infrared absorption spectrophotometry, liquid chromatography retention time against a pharmacopoeial reference standard, related substances, loss on drying, sulfated ash, and assay. The product uses no proprietary trade-name model; the batch identifier is the manufacturer’s lot code, and the specification is aligned to the current European Pharmacopoeia monograph for colchicine plus the additional controls needed for low-dose oral and injectable manufacture.

The pharmacopoeial monograph does not prescribe a particle size limit. Particle size is therefore a supplier and formulation control. For direct compression tablets at strengths of 0.5 mg or 0.6 mg, the API mass fraction can fall below 1% w/w. Under those conditions, a micronized grade is usually selected, with laser diffraction D90 controlled below 20 µm to limit segregation in a rotary tablet press. Published data for the exact D90-versus-content-uniformity response is limited, but production-scale observations on forced-feed tablet presses show that coarser crystalline fractions increase the risk of blend segregation. Micronization by a fluid energy mill reduces primary particle size but also lowers bulk density; the resulting cohesive powder can concentrate in the press feed frame if not preblended with lactose monohydrate or microcrystalline cellulose. Batch-to-batch particle size shifts should be controlled within the qualified range because colchicine is a narrow therapeutic index API and changes in dissolution rate cannot be excluded.

The related substances liquid chromatography method uses a reversed-phase C18 stationary phase with ultraviolet detection. System suitability requires resolution between colchicine and specified related compounds before acceptance. Typical reported impurities are controlled by relative retention time and impurity-specific limits; the certificate of analysis therefore reports each specified impurity, any unspecified impurity, and total impurities against the current monograph. This impurity profile is one of the main differences from older compendial tests based on melting point and total alkaloid titration. Modern liquid chromatography with diode-array detection reduces the risk that a photodegradant co-elutes with the active peak, which can be missed by non-pharmacopoeial assay methods. Crystalline form is controlled by X-ray powder diffraction as an in-process consistency parameter, even where the pharmacopoeial monograph does not name a specific polymorph.

For granules and capsules, the API can be introduced as a dry preblend or dispersed in a binder solution. Wet granulation on a high-shear mixer combined with a Frewitt cone mill and a fluid bed dryer requires control of product temperature, drying endpoint, and residual moisture. A typical drying endpoint is loss on drying 1.0–2.0%, but this range is formulation-specific. Capsule filling on dosator-type machines is more sensitive to bulk density variation than tablet compression; a shift in bulk density greater than 10% within a batch has been associated with fill weight drift. These processing boundaries are not pharmacopoeial; they must be established during process validation and protected by a supplier change-control agreement. Finished product performance is verified by dissolution testing under Ph. Eur. 2.9.3 or USP <711>.

What Controls Endotoxin Risk When the API Transitions from Oral Granules to Injectable Solutions?

Injectable-grade colchicine requires additional pre-formulation controls. The API itself is not marketed as sterile, but it is manufactured with reduced bioburden handling. Bacterial endotoxin testing is performed by Ph. Eur. 2.6.14 because pharmacological activity occurs at milligram doses, and endotoxin limits must be derived from the maximum finished product dose. The acceptance criterion for the API is set below the finished product limit to allow for dilution, holding, and filtration. Injectable manufacture also requires that the finished solution meet sub-visible particle limits under Ph. Eur. 2.9.19 and sterility under Ph. Eur. 2.6.1. Aseptic processing with 0.22 µm sterilizing-grade filtration is typical; if terminal sterilization is used, the solution must be shown stable under the qualified autoclave cycle. Light protection is required during handling because colchicine is light-sensitive. Filter compatibility studies are required with 0.22 µm PVDF and PES membranes because drug loss at low concentration can occur by adsorption. Published data on adsorption under clinical-scale filtration is limited, but mass balance should be assessed before final batch record parameters are fixed. In multi-use aseptic filling, hold times in buffer are limited by photodegradation and microbial control; the solution is protected from light and held at a validated temperature. The difference from oral granule production is therefore not merely a change in container; injectable grade adds endotoxin, bioburden, particulate, and water quality controls while retaining the same chemical impurity profile.

Low-Dose Direct Compression and Fluid Bed Granulation Parameters

At tablet strengths of 0.5 mg to 0.6 mg, content uniformity is controlled less by chemical purity and more by particle size distribution, bulk density, and blending time. Direct compression formulations often use a three-step tumble blend with a low-shear blender at 60–70% of rated vessel capacity. API is added between two excipient layers to reduce adhesion to vessel walls. Production-scale observations on a 45-station rotary tablet press with a forced feed frame indicate that fine API can concentrate in dead zones if the feed frame paddle speed is too low. In contrast, capsule manufacture using dosator nozzles may require a pre-compacted slug or granulation to normalize bulk density. Wet granulation is performed with a high-shear mixer; the wet mass is milled through a cone mill with a screen opening in the range of 0.8–1.0 mm, then dried in a fluid bed dryer with inlet air dew point below 8°C and product temperature maintained below 50°C until the target loss on drying is reached. These temperatures are conservative process bounds and are not derived from the pharmacopoeial monograph; they must be confirmed by forced degradation and thermal stability data for the specific formulation. The drying endpoint window can be narrow because solid-state degradation may increase above a defined temperature, while a lower temperature may extend drying time and reduce throughput. Published data for colchicine solid-state degradation kinetics in formulated granules is limited; therefore, a forced degradation study is part of process qualification.

Finished product dissolution is measured by Ph. Eur. 2.9.3 or USP <711>. Disintegration is assessed under Ph. Eur. 2.9.1 or USP <701>. For a narrow therapeutic index drug, any change in API particle size, polymorphic form, or supplier requires a demonstration of dissolution profile similarity or bioequivalence. The Ph. Eur. monograph does not identify a specific crystalline form; therefore X-ray powder diffraction is used as an in-process control to ensure batch consistency. Published data comparing amorphous and crystalline colchicine dissolution is limited, but amorphous material should not be assumed acceptable without validation because the pharmacopoeial specification is based on crystalline reference material. Tablet coating with an opaque or colored film is often used to reduce light exposure. Near-infrared monitoring of blend homogeneity below 1% w/w API can be insufficient without a validated multivariate model; in such cases, stratified sampling and liquid chromatography remain the reference method for content uniformity following Ph. Eur. 2.9.40 or USP <905>.

When Technical-Grade Colchicine Is Compared with Pharmacopoeial Grade

Non-pharmacopoeial colchicine is sold for plant polyploidy induction and as a laboratory reagent. Such material is not released under pharmaceutical cGMP and may lack the ICH Q3C and ICH Q3D profiles. A technical-grade lot can contain residual dichloromethane above the ICH Q3C concentration limit of 600 ppm if that solvent is used in extraction or crystallization; a pharmaceutical grade must report the actual concentration below that limit. Botanical extracts standardized to colchicine may contain related alkaloids such as colchicoside, 3-demethylcolchicine, or β-lumicolchicine, which are only partially separated by the monograph liquid chromatography method unless the specified system suitability conditions are met. The Ph. Eur. grade is not defined by total alkaloid content but by assay, related substances, residual solvents, elemental impurities, and specific monograph tests. Substitution with technical-grade or botanical-extract material in a registered finished product is not permitted without prior approval and comparability testing under 21 CFR 314.70 or equivalent post-approval change guidance. The oral and injectable API are the same chemical entity; injectable grade adds microbial and particulate controls, while oral grade may accept a broader particle size range, but both share the same chemical impurity profile. This distinction is a supply-chain and quality-system difference rather than a structural difference in the molecule.

Storage is controlled at room temperature with protection from light. The API is a potent alkaloid; operator exposure limits and containment should be assessed under occupational toxicology. For injectable manufacture, the material is transferred into a controlled environment with contained powder handling equipment to limit cross-contamination. Because colchicine is a narrow therapeutic index compound, cross-contamination limits in shared facilities should be based on health-based exposure limits, not arbitrary acceptance criteria. Cleaning validation should include swab and rinse sampling with liquid chromatography detection limits below the derived carryover threshold. Published data for colchicine carryover on specific tablet press models is limited, so cleaning verification is product-specific and must be established during process qualification.